Shanghai Haohai Biological Tech Co Total Assets
Shanghai Haohai Biological Tech Co total assets. Based on the latest financial reports, Shanghai Haohai Biological Tech Co (688366) holds total assets worth CN¥7.12 Billion CNY (≈ $1.04 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is Shanghai Haohai Biological Tech Co worth for the company's overall valuation and market capitalisation.
Total Assets of Shanghai Haohai Biological Tech Co (2012–2024)
Total assets of Shanghai Haohai Biological Tech Co from 2012 to 2024. This chart illustrates how Shanghai Haohai Biological Tech Co's total assets have evolved over time, based on quarterly financial data. See 688366 live share price for real-time trading data and today's change.
Shanghai Haohai Biological Tech Co - Asset Composition Analysis
Shanghai Haohai Biological Tech Co Total Assets Breakdown (December 2024)
Shanghai Haohai Biological Tech Co total assets breakdown as of December 2024. Shanghai Haohai Biological Tech Co's total assets of CN¥7.12 Billion consist of 51.4% current assets and 48.6% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 36.9% |
| Accounts Receivable | CN¥369.34 Million | 5.2% |
| Inventory | CN¥490.65 Million | 6.9% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥705.10 Million | 9.9% |
| Goodwill | CN¥422.93 Million | 5.9% |
Asset Composition Trend (2012–2024)
This chart illustrates how Shanghai Haohai Biological Tech Co's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is Shanghai Haohai Biological Tech Co's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shanghai Haohai Biological Tech Co's current assets represent 51.4% of total assets in 2024, a decrease from 54.8% in 2012.
- Cash Position: Cash and equivalents constituted 36.9% of total assets in 2024, up from 35.9% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 14.0% of total assets, an increase from 1.0% in 2012.
- Asset Diversification: The largest asset category is intangible assets at 9.9% of total assets.
Shanghai Haohai Biological Tech Co Competitors by Total Assets
Key competitors of Shanghai Haohai Biological Tech Co based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥28.15 Billion |
Shanghai Haohai Biological Tech Co - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.77 | 4.30 | 8.78 |
| Quick Ratio | 3.24 | 3.71 | 8.20 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥2.66 Billion | CN¥2.84 Billion | CN¥3.38 Billion |
Shanghai Haohai Biological Tech Co - Advanced Valuation Insights
This section examines the relationship between Shanghai Haohai Biological Tech Co's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.85 |
| Latest Market Cap to Assets Ratio | 0.12 |
| Asset Growth Rate (YoY) | 0.2% |
| Total Assets | CN¥7.12 Billion |
| Market Capitalization | $834.98 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shanghai Haohai Biological Tech Co's assets below their book value (0.12x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Shanghai Haohai Biological Tech Co's assets grew by 0.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Shanghai Haohai Biological Tech Co (2012–2024)
The table below shows the annual total assets of Shanghai Haohai Biological Tech Co from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥7.12 Billion ≈ $1.04 Billion |
+0.22% |
| 2023-12-31 | CN¥7.11 Billion ≈ $1.04 Billion |
+3.09% |
| 2022-12-31 | CN¥6.89 Billion ≈ $1.01 Billion |
-0.83% |
| 2021-12-31 | CN¥6.95 Billion ≈ $1.02 Billion |
+10.35% |
| 2020-12-31 | CN¥6.30 Billion ≈ $921.70 Million |
+2.39% |
| 2019-12-31 | CN¥6.15 Billion ≈ $900.21 Million |
+38.67% |
| 2018-12-31 | CN¥4.44 Billion ≈ $649.18 Million |
+8.86% |
| 2017-12-31 | CN¥4.08 Billion ≈ $596.34 Million |
+10.34% |
| 2016-12-31 | CN¥3.69 Billion ≈ $540.46 Million |
+30.88% |
| 2015-12-31 | CN¥2.82 Billion ≈ $412.93 Million |
+275.30% |
| 2014-12-31 | CN¥751.90 Million ≈ $110.03 Million |
+21.04% |
| 2013-12-31 | CN¥621.18 Million ≈ $90.90 Million |
+38.64% |
| 2012-12-31 | CN¥448.04 Million ≈ $65.56 Million |
-- |
About Shanghai Haohai Biological Tech Co
Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in China, Europe, the United States, and internationally. It offers ophthalmology products consist of intraocular lens, medical sodium hyaluronate gel, and lubricant eye drop. The company also offers sodium hyaluronate injection, medical chitosan, medical sodium hyal… Read more